RxDoctor Payments Data

Francisco Fantauzzi, MD

Family Medicine · Savannah, GANPI 1821161688

Payments from drug & device makers

$9,615in general payments, 2019–2025

Across 560 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$924
  • AstraZeneca$772
  • Amgen$718
  • Pfizer$388
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$9,582100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,615 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$74,361
Medicare patients
250
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$133,887
EliquisApixaban93$96,240
FarxigaDapagliflozin Propanediol50$66,694
JardianceEmpagliflozin61$66,116
JanuviaSitagliptin Phosphate22$28,252
TrulicityDulaglutide27$26,708
LinzessLinaclotide26$23,604
OxycontinOxycodone Hcl13$22,805
XareltoRivaroxaban19$18,383
MounjaroTirzepatide15$17,535
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,907
JanumetSitagliptin Phos/Metformin Hcl14$11,929
GemtesaVibegron15$10,150
Tresiba Flextouch U-100Insulin Degludec19$9,368
Ondansetron OdtOndansetron15$6,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,469$133,887103 claims
PfizerEliquis$388$96,24093 claims
AstraZenecaFarxiga$772$66,69450 claims
Boehringer IngelheimJardiance$379$66,11661 claims
Lilly USA, LLCTrulicity, Mounjaro$924$44,24342 claims
MerckJanuvia, Janumet$126$40,18136 claims
AbbVieLinzess, Synthroid$1,281$25,58663 claims
GSKTrelegy Ellipta, Breo Ellipta$172$21,00536 claims
Johnson & JohnsonXarelto$32$18,38319 claims
Sumitomo Pharma America, Inc.Gemtesa$33$10,15015 claims
Sanofi-aventis U.S. LLCLantus$186$2,38414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →